AUS
NZ
UK
CA
USA
IND
Highlights
- FDA approves Telix’s next-gen prostate cancer imaging agent
- Gozellix® offers wider access through extended shelf life
- Reimbursement eligibility improves patient reach
Telix Pharmaceuticals Limited (ASX:TLX) has achieved a major regulatory milestone with the U.S. Food and Drug Administration (FDA) granting approval for Gozellix® (TLX007-CDx), a next-generation PSMA-PET imaging agent designed to enhance prostate cancer diagnosis. This approval represents a significant step forward in the detection and management of prostate cancer, especially for patients in underserved areas.
Gozellix® is a gallium-68-based PSMA-PET imaging agent, tailored to improve the identification of PSMA-positive lesions in men suspected of prostate cancer metastasis or recurrence due to elevated PSA levels. A standout feature of Gozellix® is its extended shelf life of up to six hours, a considerable improvement over current gallium-based imaging products. This extended viability enhances the logistical reach of the agent, enabling broader distribution and ensuring that more medical facilities across the U.S. have access to high-quality imaging.
The ability of Gozellix® to travel farther from production sites also means it can support a wider range of PET scanners, reaching regions that were previously difficult to serve. As a result, more patients are likely to benefit from advanced imaging technology, improving early detection and the overall management of prostate cancer.
Additionally, Gozellix® is expected to qualify for full reimbursement in the U.S. healthcare system, which will ease the financial burden for healthcare providers and make the diagnostic tool more accessible to a broader patient population. This development aligns with efforts to reduce disparities in cancer care and ensure that cutting-edge medical technology is available to those who need it most.
Kevin Richardson, CEO of Telix Precision Medicine, expressed the company’s commitment to continuous innovation. He highlighted that Gozellix® brings a new level of reliability, service, and flexibility, further strengthening the company’s presence in the U.S. diagnostics landscape.
The approval of Gozellix® marks not only a technological leap but also a meaningful advancement in patient access and equity in cancer care. With this milestone, Telix (TLX) reinforces its role as a key player in the development of precision imaging solutions for serious diseases, further expanding its footprint in global healthcare innovation.
